'For the quarter ending June 2023, consolidated Net sales (including other operating income) of Aurobindo Pharma has increased 9.86% to Rs 6850.52 crore compared to quarter ended June 2022. Operating profit margin has jumped from 15.02% to 16.81%, leading to 22.95% rise in operating profit to Rs 1,151.37 crore.  Raw material cost as a % of total sales (net of stock adjustments) increased from 34.39% to 39.20%.   Purchase of finished goods cost fell from 8.36% to 8.25%.   Employee cost decreased from 15.05% to 13.54%.   Other expenses fell from 26.20% to 22.64%.   

Other income rose 186.39% to Rs 116.33 crore.  PBIDT rose 29.74% to Rs 1267.7 crore.  Provision for interest rose 286.53% to Rs 56.55 crore.  

PBDT rose 25.84% to Rs 1211.15 crore.  Provision for depreciation rose 16.83% to Rs 326.56 crore.  

Profit before tax grew 29.52% to Rs 884.59 crore. ...

• 

  (13-Jan-2026)

  ICICI Prudential Life Insurance Company

  Net profit jumps 20%, VNB improves in Q3FY2026
• 

  (13-Jan-2026)

  G G Automotive Gears

  Net up 33% on strong operating show
• 

  (13-Jan-2026)

  HCL Technologies

  Revenue up 13.3% YoY to Rs 33872 crore in Q3FY2026
• 

  (13-Jan-2026)

  Tata Consultancy Services

  Revenue up 4.9% YoY to Rs 67087 crore in Q3FY2026